Hemostemix Inc. (TSXV: HEM)
Health Care · Biotechnology · CA
CA$0.07
-6.67% today · 0.0% 1Y
Hemostemix Inc. (TSXV: HEM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $10.78M and employs 12 people.
Over the last twelve months the share price has gained 0.0%, trading between 0.04 and 0.14.
Tweenvest scores Hemostemix Inc. across four factors: quality 0/100. Its strongest factor is quality.
HEM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $10.78M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- 0.61
- 52-week high
- CA$0.14
- 52-week low
- CA$0.04
- Avg volume (3M)
- —
- Shares outstanding
- 197.82M
- Employees
- 12
- Next earnings
- —
About Hemostemix Inc.
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
- ISIN
- CA4236943060
- Listed since
- Nov 28, 2014
- Exchange
- TSX Venture Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.75 | -0.02% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $441.55 | -0.16% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €898.00 | +2.14% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $157.87 | -0.60% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.